Keros Therapeutics Halts Treatment In 3.0 Mg/Kg and 4.5 Mg/Kg Treatment Arms In Ongoing TROPOS Trial Over Safety Concerns
Keros Therapeutics Halts Treatment In 3.0 Mg/Kg and 4.5 Mg/Kg Treatment Arms In Ongoing TROPOS Trial Over Safety Concerns
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Keros Therapeutics, Inc.（“Keros” 或 “公司”）（纳斯达克股票代码：KROS）是一家临床阶段的生物制药公司，专注于开发和商业化新疗法，以治疗与转化生长因子β（“TGF-β”）蛋白质家族信号失调相关的各种疾病患者，今天宣布自愿停止给药3.0 mg/s 正在进行的 TROPOS 试验中 kg 和 4.5 mg/kg 治疗组，这是一项针对以下患者的西博特西普（KER-012）联合背景疗法的 2 期临床试验肺动脉高压（“PAH”），基于一项安全审查，这是由于在试验中意外观察到心包积液不良事件所致。
